-
1 Comment
Ocumension Therapeutics is currently in a long term uptrend where the price is trading 9.1% above its 200 day moving average.
From a valuation standpoint, the stock is 302.0% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 452.4.
Based on the above factors, Ocumension Therapeutics gets an overall score of 1/5.
| Exchange | HK |
|---|---|
| CurrencyCode | HKD |
| Sector | Healthcare |
| Industry | Biotechnology |
| ISIN | KYG674111011 |
| Market Cap | 4B |
|---|---|
| PE Ratio | None |
| Target Price | 7.3224 |
| Beta | 0.81 |
| Dividend Yield | None |
Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. It discovers, develops, and commercializes therapies for ophthalmic patients. Its portfolio includes products and drugs for the treatment of chronic non-infectious uveitis, infective and allergic conjunctivitis, diabetic macular edema, dry eye, glaucoma and ocular hypertension, postoperative inflammation, choroidal neovascularization, bacterial conjunctivitis, retinitis pigmentosa, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis. It had various drug assets in its portfolio. The company was founded in 2017 and is based in Suzhou, the People's Republic of China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 1477.HK using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
